MOA Life Plus Co. Ltd.

Company Profile

Sector

Healthcare

Industry

Biotechnology

Employees

N/A

Website

www.moalifeplus.com

Country

South Korea

Exchange

KOSDAQ

Founded 1999Yongin-Si, South Korea

MOA Life Plus provides the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company's pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer.

Its portfolio also includes BLC-H03, a vaccine adjuvant that is in preclinical stage, BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer, and BLS-M22 that has completed phase 1 clinical trial for the treatment of Duchenne muscular dystrophy

Health functional food and raw materials, and cosmetics. Founded in 1999 and headquartered in Yongin-Si, South Korea, MOA Life Plus was formerly known as Bioleaders Corporation before rebranding in March 2024.

Key Stats

52-Week Range

₩340.00₩2180.00

BetaN/A

Trailing P/EN/A

Forward P/EN/A

Trailing EPSN/A

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.